Microbial communities known as biofilms, which are affixed to biotic or abiotic surfaces and shielded by an extracellular polymeric matrix, have been the subject of much research in the last several years. According to estimates, biofilm-forming microorganisms cause about 65% of microbial infections. These microorganisms pose a serious threat to public health because they can evade the host immune system and are resistant to most antimicrobials used in treatment, which prolong the infection. Biofilms also exacerbate the problem of treating and eliminating infections, particularly those that originate in and on invasive devices like implants and catheters, and drive up hospital expenses and morbidity and mortality rates. The majority of the time, biofilms result in chronic infections, which withstand both the host’s innate and adaptive defense mechanisms and seemingly sufficient antibiotic therapy. The pathology associated with chronic infections is ongoing and progressive, primarily because of the inflammatory reaction around the biofilm. This further implies that the only characteristic shared by different biofilm infections is persistent local inflammation, while other indications and symptoms are contingent upon the degree of function impairment of the foreign body or organ infected by the microbial biofilm. Because the majority of biofilm-related infections have nonspecific signs and symptoms, diagnosing these infections remains difficult. In research laboratories, biofilms can be diagnosed using a variety of techniques, but in clinical practice, there is not a set protocol for this kind of diagnosis. Furthermore, planktonic bacteria are still used in antimicrobial susceptibility tests, which is not representative of the clinical situation when an infection linked to biofilms occurs. Researchers are also actively investigating the early detection of infections through the use of biosensors and hyperspectral imaging techniques, as well as the prevention and management of biofilm formation on materials surfaces such as titanium, stainless steel, and titanium alloys. Blood tests for elevated leukocyte counts, MRIs, C-T scans, atomic force microscopy (AFM), and colony-forming unit (CFU) counting are among the current diagnostic techniques. Nevertheless, biofilm-based infections are not effectively diagnosed even with these available techniques. Therefore, there is a desire to advance and create novel methods of diagnosis and quantification. These methods include Fourier transform infrared spectroscopy, AFM, confocal scanning laser microscopy, light microscopy, scanning electron microscopy (SEM), radiolabeling, contact angle measurements, and qPCR. They have also been improved to count CFUs. Low frequencies (10–100 Hz) have been shown to be more sensitive for Staphylococcus epidermidis detection in an interdigitated microelectrode sensor system developed using impedance microbiology, which can identify the presence of microorganisms in samples. Another label-free method for molecular sensing that is currently being researched extensively is surface-enhanced Raman spectroscopy (SERS). Typically, Raman spectra have a large number of distinct peaks that are indicative of particular molecular vibrational frequencies and can be used to identify which molecules are present in a sample. Salmonella, Listeria, Escherichia coli, S. epidermidis, and Bacillus can now be effectively detected on bacterial cell walls by synthesizing silver nanoparticles thanks to the high sensitivity of SERS. Bacterial sensing and detection technologies will be essential in the clinical setting for preventing biofilm-causing infections because, as previously stated, preventing bacterial biofilms is a better strategy than eliminating pre-formed biofilms.